Potential Anti-cancer Drugs Commonly Used for Other Indications

被引:64
作者
Hanusova, Veronika [1 ]
Skalova, Lenka [2 ]
Kralova, Vera [1 ]
Matouskova, Petra [2 ]
机构
[1] Charles Univ Prague, Fac Med, Dept Med Biol & Genet, CZ-50038 Hradec Kralove, Czech Republic
[2] Charles Univ Prague, Fac Pharm, Dept Biochem Sci, CZ-50005 Hradec Kralove, Czech Republic
关键词
Anthelmintics; anti-cancer effect; antidiabetics; antihypertensive; antipsychotics; cancer drug repurposing; ACTIVATED-RECEPTOR-GAMMA; EPITHELIAL-MESENCHYMAL TRANSITION; CANCER-CELL-PROLIFERATION; NF-KAPPA-B; BREAST-CANCER; IN-VITRO; ANTIDIABETIC THIAZOLIDINEDIONES; MULTIDRUG-RESISTANCE; GROWTH-INHIBITION; INDUCE APOPTOSIS;
D O I
10.2174/1568009615666141229152812
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An increasing resistance of mammalian tumor cells to chemotherapy along with the severe side effects of commonly used cytostatics has raised the urgency in the search for new anti-cancer agents. Several drugs originally approved for indications other than cancer treatment have recently been found to have a cytostatic effect on cancer cells. These drugs could be expediently repurposed as anti-cancer agents, since they have already been tested for toxicity in humans and animals. The groups of newly recognized potential cytostatics discussed in this review include benzimidazole anthelmintics (albendazole, mebendazole, flubendazole), anti-hypertensive drugs (doxazosin, propranolol), psychopharmaceuticals (chlorpromazine, clomipramine) and antidiabetic drugs (metformin, pioglitazone). All these drugs have a definite potential to be used especially in combinations with other cytostatics; the chemotherapy targeting of multiple sites now represents a promising approach in cancer treatment. The present review summarizes recent information about the anti-cancer effects of selected drugs commonly used for other medical indications. Our aim is not to collect all the reported results, but to present an overview of various possibilities. Advantages, disadvantages and further perspectives regarding individual drugs are discussed and evaluated.
引用
收藏
页码:35 / 52
页数:18
相关论文
共 186 条
[1]   CANCER RISK IN PATIENTS WITH DIABETES-MELLITUS [J].
ADAMI, HO ;
MCLAUGHLIN, J ;
EKBOM, A ;
BERNE, C ;
SILVERMAN, D ;
HACKER, D ;
PERSSON, I .
CANCER CAUSES & CONTROL, 1991, 2 (05) :307-314
[2]   Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases [J].
Allarakhia, Minna .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 :753-766
[3]   NCATS launches drug repurposing program [J].
Allison, Malorye .
NATURE BIOTECHNOLOGY, 2012, 30 (07) :571-572
[4]   Pharmacological targeting of β-adrenergic receptor functions abrogates NF-κB signaling and MMP-9 secretion in medulloblastoma cells [J].
Annabi, Borhane ;
Vaillancourt-Jean, Eric ;
Weil, Alexander G. ;
Beliveau, Richard .
ONCOTARGETS AND THERAPY, 2010, 3 :219-226
[5]   Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion [J].
Annabi, Borhane ;
Lachambre, Marie-Paule ;
Plouffe, Karine ;
Moumdjian, Robert ;
Beliveau, Richard .
PHARMACOLOGICAL RESEARCH, 2009, 60 (05) :438-445
[6]   Therapeutic Potential of an Anti-diabetic Drug, Metformin: Alteration of miRNA expression in Prostate Cancer Cells [J].
Avci, Cigir Biray ;
Harman, Ece ;
Dodurga, Yavuz ;
Susluer, Sunde Yilmaz ;
Gunduz, Cumhur .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (02) :765-768
[7]   Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme [J].
Bai, Ren-Yuan ;
Staedtke, Verena ;
Aprhys, Colette M. ;
Gallia, Gary L. ;
Riggins, Gregory J. .
NEURO-ONCOLOGY, 2011, 13 (09) :974-982
[8]   Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells [J].
Bao, Bin ;
Wang, Zhiwei ;
Ali, Shadan ;
Ahmad, Aamir ;
Azmi, Asfar S. ;
Sarkar, Sanila H. ;
Banerjee, Sanjeev ;
Kong, Dejuan ;
Li, Yiwei ;
Thakur, Shivam ;
Sarkar, Fazlul H. .
CANCER PREVENTION RESEARCH, 2012, 5 (03) :355-364
[9]   Metformin: A Rising Star to Fight the Epithelial Mesenchymal Transition in Oncology [J].
Barriere, Guislaine ;
Tartary, Michel ;
Rigaud, Michel .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (02) :333-340
[10]   Beta Blockers and Breast Cancer Mortality: A Population-Based Study [J].
Barron, Thomas I. ;
Connolly, Roisin M. ;
Sharp, Linda ;
Bennett, Kathleen ;
Visvanathan, Kala .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) :2635-2644